&nbsp;

Dec 2022

Drug

inotuzumab ozogamicin

Other Name(s): Besponsa®

Quick Link(s):

Jul 2023

Drug

gemtuzumab ozogamicin

Other Name(s): Mylotarg®

Quick Link(s):

Jun 2022

Drug

liposomal DAUNOrubicin / liposomal cytarabine

Other Name(s): Vyxeos®

Quick Link(s):

Dec 2023

Drug

treosulfan

Other Name(s): Trecondyv®

Quick Link(s):

Drug Monograph

Jan 2025

Drug

calaspargase pegol

Other Name(s): Asparlas®

Quick Link(s):

Apr 2025

Regimen

TECL; TECL(RAMP)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma

High Cost Therapy Funding Program

Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma

Drugs Used:

teclistamab

Quick Link(s):

Regimen Monograph

Jul 2025

Drug

teclistamab

Other Name(s): Tecvayli®

Quick Link(s):

Jul 2025

Drug

glofitamab

Other Name(s): Columvi®

Quick Link(s):

Updated

Aug 2025

Regimen

GLOF; GLOF(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Glofitamab (Outpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

High Cost Therapy Funding Program

Glofitamab (Inpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

Drugs Used:

oBINutuzumab,

glofitamab

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

TEBE; TEBE(RAMP)

Cancer Type:

Skin,

Melanoma

Intent: Palliative

Funding:

New Drug Funding Program

Tebentafusp (Outpatient) - Unresectable or Metastatic Uveal Melanoma

High Cost Therapy Funding Program

Tebentafusp (Inpatient) - Unresectable or Metastatic Uveal Melanoma

Drugs Used:

tebentafusp

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

EPCO; EPCO(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

High Cost Therapy Funding Program

Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Drugs Used:

epcoritamab